Thomas A. Olson

Emory University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

A. Lindsay Frazier

Dana-Farber Cancer Institute

Deborah F. Billmire

Indiana University School of Medicine

Mark Krailo

Children's Oncology Group

Carlos Rodríguez‐Galindo

St. Jude Children's Research Hospital

Farzana Pashankar

Yale University

James F. Amatruda

Children's Hospital of Los Angeles

Furqan Shaikh

SickKids Foundation

Marcio H. Malogolowkin

UC Davis Comprehensive Cancer Center

Howard M. Katzenstein

Ono Pharmaceutical (United States)

Sara Stoneham

University College London Hospitals NHS Foundation Trust

Cooperative Institutions

Emory University

112

Children's Healthcare of Atlanta

University of Pennsylvania

Harvard University

Boston Children's Hospital

Children's Hospital of Philadelphia

Pediatrics and Genetics

University of Washington

Dana-Farber Cancer Institute

University of California, San Francisco

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Adolescents and Young Adults With a “Rare” Cancer: Getting Past Semantics to Optimal Care for Patients With Germ Cell Tumors

The Oncologist (2014)

Sara Stoneham Juliet Hale Carlos Rodríguez‐Galindo Ha Dang Thomas A. Olson

Because the tumors of adolescence and young adulthood (AYA) are distinct from those that occur earlier and later in life, the most common tumors in this age group are termed “rare.” We offer a collaborative, cross-disciplinary, evidence-based approach, advocated and funded by civil society, to advance the field of germ cell tumor and potentially to apply to other rare AYA tumors.

10.1634/theoncologist.2014-0009

Cite

Citations (15)

Atlanta Update: Myeloablative HLA-Matched Sibling Donor (MSD) Bone Marrow Transplantation (BMT) for 18 Children With Severe Sickle Cell Disease (SCD)

Journal of Pediatric Hematology/Oncology (2005)

Ann E. Haight Carrye Anne Rudolph James R. Eckman Lewis L. Hsu Laura C. Bowman

Haight, Ann E MD; Rudolph, Carrye Anne BS; Eckman, James R MD; Hsu, Lewis L MD, PhD; Bowman, Laura C MD; Chiang, Kuang-Yueh MD, PhD; Olson, Ellen RN, CPNP; Lauer, Mary RN, CPNP; Yeager, Andrew M MD; Adamkiewicz, Thomas MD; Lane, Peter MD; Olson, Thomas MD Author Information

Atlanta

10.1097/01.mph.0000188523.48265.31

Cite

Citations (0)

Graduation Requirements as a Vehicle for Change.

Thomas A. Olson

Graduation (instrument)

Source

Cite

Citations (0)

Chemoradiation for Pediatric Primary Cardiac Leiomyosarcoma: Case Report and Review of Literature

Authorea (Authorea) (2021)

James Janopaul‐Naylor Kirk R. Kanter Thomas A. Olson Bree R. Eaton

A 13-year-old healthy girl presented with dizziness and palpitations, found to have a left atrial mass. An 8 cm tumor was removed. Pathology confirmed leiomyosarcoma, Grade 3 with positive margins. She was treated with ifosfamide and doxorubicin prior to radiation with concurrent ifosfamide alone. She was treated to 66 Gy in 33 fractions to the operative bed. Prospectively graded toxicities included Gr 2 esophagitis and Gr 1 anorexia, dermatitis and fatigue. She completed a total of 6 cycles of ifosfamide. One year after treatment she had no evidence of disease with normal ECHO and no cardiac, pulmonary or esophageal symptoms.

Palpitations

Anorexia

10.22541/au.161919711.17267446/v1

Cite

Citations (0)

Rare Tumors: A Different Perspective on Oncology

Pediatric oncology (2011)

Thomas A. Olson Dominik T. Schneider Ines B. Brecht Andrea Ferrari

Childhood Cancer

Cancer Incidence

10.1007/978-3-642-04197-6_1

Cite

Citations (7)

MICROMEGAKARYOCYTOSIS AND HEREDITARY THROMBOCYTOPENIA

Pediatric Research (1987)

Thomas A. Olson Richard F. Levine Pamela K Shoff John F. Kelleher

Feulgen stain

Thrombocytopenic purpura

10.1203/00006450-198704010-00817

Cite

Citations (0)

NEUTROPHIL AGGREGATION IN VITRO BY AMPHOTERICIN-B

Pediatric Research (1984)

Thomas A. Olson Bruce A. Cook Doris P Burgess Frederick B. Ruymann

Bovine serum albumin

10.1203/00006450-198404001-00916

Cite

Citations (0)

P615: Low rate of clinical follow-up for potential germline variants identified in hematologic malignancies with a next generation sequencing panel

Genetics in Medicine Open (2024)

Hannah Wollenzien Thomas A. Olson Kelly Rafferty Scott A. Turner Andrea Ferreira‐Gonzalez

Somatic tests are used routinely in clinical practice to identify variants present in a malignancy. While somatic testing cannot definitively identify germline variants, it can raise suspicion of this possibility. Potentially germline variants identified on somatic assays have implications for the patient and at-risk family members and should always be followed up with a validated germline assay. The aim of this study was to identify pathogenic variants detected via somatic next generation sequencing (NGS) in DDX41, CEBPA, PTPN11, GATA2, PTEN, or NF1 and assess clinical follow-up of potential germline status.

Hematologic Neoplasms

10.1016/j.gimo.2024.101521

Cite

Citations (0)

Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study

Pediatric Blood & Cancer (2018)

Farzana Pashankar A. Lindsay Frazier Mark Krailo Caihong Xia Alberto S. Pappo

Abstract Background Paclitaxel, ifosfamide, cisplatin (TIP) is commonly used as salvage for malignant germ cell tumors (MGCT) in adults; however, additional administration of cisplatin at a young age could cause significant short‐ and long‐term toxicities in a group of patients with high expected salvage. Because carboplatin has been shown to be effective in pediatric MGCT with less toxicity, the TIP regimen was modified by substituting carboplatin for cisplatin. Methods The Children's Oncology Group conducted a phase II trial between November 2007 and June 2011 evaluating “TIC” (paclitaxel 135 mg/m 2 /day Day 1, ifosfamide 1,800 mg/m 2 /dose Days 1–5 and carboplatin with AUC 6.5 Day 1) in children < 21 years with relapsed MGCT. The endpoint of the trial was response after two cycles, incorporating RECIST response and marker decline. Results Twenty patients (12 male, median age 13.5 years) were enrolled. Seventeen patients had tumor markers ≥10 times above normal. After two cycles, by RECIST criteria, 8 patients achieved a partial response (response rate 40%), 10 had stable disease, and 2 had progressive disease. A ≥ 1 log reduction was achieved in 10/17 patients (58.8%) with elevated markers. By study defined criteria, combining response by RECIST and marker decline, the response rate was 44%. Conclusion TIC is active in relapsed pediatric MGCT and should be considered for salvage therapy in children. In adolescents and older adults with relapse MGCT, TIP or high‐dose chemotherapy with stem cell remain the standard therapy.

Carboplatin

Salvage therapy

Regimen

Clinical endpoint

Refractory (planetary science)

10.1002/pbc.27111

Cite

Citations (12)

Tumors of Unknown Primary Site

Pediatric oncology (2022)

Thomas A. Olson

Pediatric cancer

Primary tumor

10.1007/978-3-030-92071-5_46

Cite

Citations (0)